Efficacy and Effectiveness of Antidepressants: Current Status of Research
The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Background: This paper examines the current status of research on the efficacy and effectiveness of antidepressants. Methods: This paper reviews four meta-analyses of efficacy trials submitted to America’s Food and Drug Administration (FDA) and analyzes STAR*D (Sequenced Treatment Alternatives to Relieve Depression), the largest antidepressant effectiveness trial ever conducted. Results: Meta-analyses of FDA trials suggest that antidepressants are only marginally efficacious compared to placebos and document profound publication bias that inflates their apparent efficacy. These meta-analyses also document a second form of bias in which researchers fail to report the negative results for the pre-specified primary outcome measure submitted to the FDA, while highlighting in published studies positive results from a secondary or even a new measure as though it was their primary measure of interest. The STAR*D analysis found that the effectiveness of antidepressant therapies was probably even lower than the modest one reported by the study authors with an apparent progressively increasing dropout rate across each study phase. Conclusions: The reviewed findings argue for a reappraisal of the current recommended standard of care of depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the STAR-D trial, the largest naturalistic study of antidepressants so far conducted, the remission rate at one year for all participants taking antidepressants was 2.7% (108/4000), and 92.9% relapsed or dropped out (Pigott 2010).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Pigott 2010
In the citing paper
“Currently available antidepressant medications largely target monoamine pathways, but treatment of depression is only effective in about a third to a half of patients.1, 2”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [1]
In the citing paper
“current treatment of depression is only effective in about a third to a half of patients,1, 2”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [1]
In the citing paper
“In this study, 84 % of participants in this study answered in the affirmative to a question about whether they felt antidepressants had reduced their depression, a number well above that suggested by efficacy studies”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [26]
In the citing paper
“An understanding of users’ own experiences of antidepressant use is increasingly important in the context of growing doubts about the effectiveness of antidepressant treatment [5, 26], concerns about side effects [27] and withdrawal effects [28].”
From ‘In my life antidepressants have been…’: a qualitative analysis of users’ diverse experiences with antidepressants (2016) · cites this paper as [26]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“recommendations for distinguishing between specific and nonspecific treatment effects, the first one being having an active placebo arm to reduce the likelihood of unblinding and thereby control the potential role of side effects in enhancing patients’ expectation of improvement. Real-World Effectiveness of Antidepres…”
BackgroundRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“p. 129] (table 2 ). 2 Table 2. Survival analysis by treatment step of patients who entered continuing care in remission T02 As mentioned earlier, STAR*D was designed to identify the best next-step treatment for the many patients who fail to get adequate relief from their initial SSRI trial. Due to the high study dropo…”
MethodKirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
HARKing: Hypothesizing after the results are known
Kerr, N. L. (1998) · Personality and Social Psychology Review · doi:10.1207/s15327957pspr0203_4 · Cited by 1,989
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
The Existence of Publication Bias and Risk Factors for Its Occurrence
Dickersin, K. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03440100097014 · Cited by 1,417
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“observed that early RCTs often enrolled hospitalized patients who were less responsive to placebo, whereas more recent trials typically enroll highly selected outpatients, contacted through mass media advertisements, who may be less severely depressed. In a meta-analysis of 75 RCTs published between 1981 and 2000, Wal…”
BackgroundSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“p. 739].The conclusion section of the research design article of STAR*D states: ‘STAR * D uses a randomized, controlled design to evaluate both the theoretical principles and clinical beliefs that currently guide the management of treatment-resistant depression in terms of symptoms, function, satisfaction, side-effect…”
BackgroundBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“p. 15]. While the guidelines of APA are consistent with the meta-analyses performed by Geddes et al. [”
ResultPublication bias: the case for an international registry of clinical trials.
Simes, R. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1529 · Cited by 747
Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials
Mathieu, S. (2009) · JAMA · doi:10.1001/jama.2009.1242 · Cited by 730
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication.
Kirsch, I., & Sapirstein, G. (1998) · Prevention & Treatment · doi:10.1037/1522-3736.1.1.12a · Cited by 502
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452 · cited 1×
“argues that this progressively increasing response to both compromises the ability to differentiate truly efficacious antidepressants from placebos, particularly among less severe patients.Fava et al. [”
BackgroundKirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002) · Prevention & Treatment · doi:10.1037/1522-3736.5.1.523a · Cited by 422
The emperor's new drugs: exploding the antidepressant myth
(2010) · Choice Reviews Online · doi:10.5860/choice.48-1164 · Cited by 395
Rush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385
Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.469 · Cited by 382
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0906126 · Cited by 361
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332 · cited 1×
“Possible reasons so few patients found CT acceptable included: (1) biased self-selection since all patients started on citalopram in step 1; (2) the added costs of CT which STAR*D did not cover whereas it covered all medication and physician visit costs, and (3) CT patients had to go to another site to see a new non-p…”
BackgroundRising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328 · cited 1×
“or ‘hypothesizing after the results are known’ .Rising et al. [”
BackgroundLong-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071065 · Cited by 314
How important is publication bias? A synthesis of available data.
Dickersin, K. (1997) · PubMed · Cited by 311
Major depressive subtypes and treatment response
Fava, M., Uebelacker, L. A., Alpert, J. E., Nierenberg, A. A., Pava, J. A., & Rosenbaum, J. F. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00440-4 · Cited by 247
Krleža-Jerić, K., Chan, A.-W., Dickersin, K., Sim, I., Grimshaw, J., & Gluud, C. (2005) · BMJ · doi:10.1136/bmj.330.7497.956 · Cited by 236
Can long-term treatment with antidepressant drugs worsen the course of depression?
Fava, G. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0204 · Cited by 223
Wisniewski, S. R., Rush, A. J., Nierenberg, A. A., Gaynes, B. N., Warden, D., Luther, J. F., McGrath, P. J., Lavori, P. W., Thase, M. E., Fava, M., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071027 · Cited by 223 · cited 1×
“found that RCTs would have excluded 86p due to their having a comorbid anxiety or substance use disorder, insufficient depressive symptoms, and/or current suicidal ideation. Similarly, a post hoc analysis of STAR*D (Sequenced Treatment Alternatives to Relieve Depression) patients, the largest antidepressant effectiven…”
MethodChouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · cited 1×
“p. 262] that successive pharmacological manipulations ‘may propel depressive illness into a refractory phase’ by fostering oppositional tolerance in which the antidepressant sensitizes some patients to depression. Chouinard and Chouinard [[”
BackgroundRush, A. J., Trivedi, M. H., Carmody, T. J., Ibrahim, H. M., Markowitz, J. C., Keitner, G. I., Kornstein, S. G., Arnow, B. A., Klein, D. N., Manber, R., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300614 · Cited by 154
Predictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report
Warden, D., Trivedi, M. H., Wisniewski, S. R., Davis, L., Nierenberg, A. A., Gaynes, B. N., Zisook, S., Hollon, S. D., Balasubramani, G. K., Howland, R., et al. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06071225 · Cited by 147
Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results
Chan, A.-W. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050230 · Cited by 144
Psychometric Theory Is an Obstacle to the Progress of Clinical Research
Fava, G. A., Ruini, C., & Rafanelli, C. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000076451 · Cited by 140
Continuation and Maintenance Use of Antidepressants in Recurrent Depression
Bockting, C. L. H., ten Doesschate, M. C., Spijker, J., Spinhoven, P., Koeter, M. W. J., & Schene, A. H. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000110056 · Cited by 121
Barbui, C., Furukawa, T. A., & Cipriani, A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.070693 · Cited by 121
Papakostas, G. I., Perlis, R. H., Scalia, M. J., Petersen, T. J., & Fava, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000195042.62724.76 · Cited by 117
The Road to Recovery from Depression – Don’t Drive Today with Yesterday’s Map
Fava, G. A., Tomba, E., & Grandi, S. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000104701 · Cited by 110
Raising Questions about Antidepressants
Antonuccio, D. O., Danton, W. G., DeNelsky, G. Y., Greenberg, R., & Gordon, J. S. (1999) · Psychotherapy and Psychosomatics · doi:10.1159/000012304 · Cited by 110
Lieberman, J. A., Greenhouse, J. B., Hamer, R. M., Krishnan, K. R. R., Nemeroff, C. B., Sheehan, D. V., Thase, M. E., & Keller, M. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300571 · Cited by 109
A Meta-Analysis of Fluoxetine Outcome in the Treatment of Depression
GREENBERG, R. P., BORNSTEIN, R. F., FISHER, S., ZBOROWSKI, M. J., & GREENBERG, M. D. (1994) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199410000-00003 · Cited by 105
Rethinking Models of Psychotropic Drug Action
Moncrieff, J., & Cohen, D. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000083999 · Cited by 88
Do Antidepressant and Antianxiety Drugs Increase Chronicity in Affective Disorders?
Fava, G. A. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000288880 · Cited by 73
Treatment of Recurrent Depression: A Sequential Psychotherapeutic and Psychopharmacological Approach
Fava, G. A., Ruini, C., & Sonino, N. (2003) · CNS Drugs · doi:10.2165/00023210-200317150-00005 · Cited by 69
Faravelli, C. (2004) · Psychotherapy and Psychosomatics · doi:10.1159/000076449 · Cited by 63
The Psychosomatic Assessment: Strategies to Improve Clinical Practice
(2011) · Advances in Psychosomatic Medicine · doi:10.1159/isbn.978-3-8055-9854-5 · Cited by 45
Gaudiano, B. A., & Herbert, J. D. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082022 · Cited by 43
Assay Sensitivity, Failed Clinical Trials, and the Conduct of Science
Otto, M. W., & Nierenberg, A. A. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000064813 · Cited by 42
Antidepressants on trial: how valid is the evidence?
Parker, G. B. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.054767 · Cited by 39
Antidepressants and placebos: Secrets, revelations, and unanswered questions.
Kirsch, I., Scoboria, A., & Moore, T. J. (2002) · Prevention & Treatment · doi:10.1037/1522-3736.5.1.533r · Cited by 33
Mental Health Clinics in the 21st Century
Marks, I. M. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000206865 · Cited by 25
The mental health clinic: a new model
Fava, G. A., PARK, S. K., & Dubovsky, S. L. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00192.x · Cited by 23
Research works printed but not linked: 9
- 10.1001%2Fjama.263.10.1385 · DOI
- 10.1176%2Fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2Fappi.ajp.163.9.1519 · DOI · Paper page
- 10.1176%2Fappi.ajp.163.9.1531 · DOI
- 10.1176%2Fappi.ajp.163.11.1905 · doi:10.1176/appi.ajp.163.11.1905 · Paper page
- 10.1176%2Fappi.ajp.164.5.739 · DOI · Paper page
- 10.1001%2Fjama.287.13.1646 · DOI
- 10.1159%2F000235736 · DOI · Paper page
- 10.1016%2FS0895-4356%2899%2900161-4 · DOI · Paper page
Cited by
Fried, E. I., & Nesse, R. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.010 · Cited by 1,043
“…et al., 2013), the striking lack of progress in identifying biomarkers associated with depression diagnosis or treatment response (Hek et al., 2013; Kapur et al., 2012; Tansey et al., 2012), and the low efficacy of antidepressants in clinical trials (Kirsch et al., 2008; Pigott et al., 2010).”
Depression sum-scores don’t add up: why analyzing specific depression symptoms is essential
Fried, E. I., & Nesse, R. M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0325-4 · Cited by 981
“Several large meta-analyses of clinical trials have demonstrated that antidepressants outperform placebos in less than half of the trials, and that clinically relevant improvements can be documented only for a minority of severely depressed patients [32-34].”
BackgroundThe Impact of Individual Depressive Symptoms on Impairment of Psychosocial Functioning
Fried, E. I., & Nesse, R. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090311 · Cited by 424
Fried, E. I. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00309 · Cited by 367
“REVIEW published: 23 March 2015 doi: 10.3389/fpsyg.2015.00309 Edited by: Antoine Bechara, University of Southern California, USA Reviewed by: John Monterosso, University of Southern California, USA Richard McNally, Harvard University, USA *Correspondence: Eiko I. Fried, Research Group of Quantitative Psychology and In…”
BackgroundInfluentialMeta-review of depressive subtyping models
Harald, B., & Gordon, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.07.015 · Cited by 328
“Finally, and most importantly, the comparable efficacy of psychotherapies and antidepressant medication treatments (Baumeister et al., 2011, in press; Cuijpers et al., 2010; Ghaemi, 2008; Kirsch et al., 2008; Pigott et al., 2010; Turner et al., 2008) does not allow us to deduce specific treatment strategies for those…”
Background
Metadata
- Authors
- Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J.
- Affiliations
- American University (US)
- ORCID
- Pigott, H. Edmund
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 79
- Issue
- 5
- Pages
- 267-279
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2020265264
- Cited by
- 347
- References
- 58
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 23 · 2020: 18 · 2019: 22 · 2018: 22 · 2017: 16 · 2016: 19 · 2015: 42 · 2014: 22 · 2013: 20 · 2012: 26
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, depression, antidepressant efficacy, publication bias, STAR*D trial, meta-analysis, selective outcome reporting, dropout rates
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Humans, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Publication Bias, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.